DANISH BIOTECH CHARGING AHEAD
Jun. 9, 2008 | Topic: Life ScienceNew survey from Ernst & Young shows that Denmark is the country in Europe in which third most new drugs under development. The biotech industry attracts capital as never before and is in a positive spiral.
New survey from Ernst & Young shows that Denmark is the country in Europe in which third most new drugs under development. The biotech industry attracts capital as never before and is in a positive spiral.
The number of medicinal drugs under development in Danish biotech companies increased by 25 percent from 2006-2007. In comparison the average increase in Europe was 9 percent.
New figures from Ernst & Young disclose that Denmark with 188 budding product possibilities is occupying 3rd place in Europe in the competition about developing most new biotech products – surpassed only by Great Britain and Germany, writes Ingeniøren.
“Denmark is doing excellently with regard to the number of candidates as well as raised capital. It is very impressive when looking at the number of inhabitants,” says Consultant Lisa Almén from Ernst & Young. Drugs against cancer and HIV are for example under development.
Moreover, Danish Biotech is very good at raising capital. DKK 3.4 billion was raised in 2007 – fourth most in Europe.
Also on the up-start side things are progressing. In 2007, 11 new biotech companies were established in Denmark – almost double compared with 2005.
A strong biotech industry creates workplaces, export as well as generates further research by bridging companies and universities in which the entrepreneurs are often starting. In short biotech is a field in which Denmark can compete with China, states Lisa Almén.
“To do world-class research rather than being the cheapest counts within the biotech industry.”